A Phase I/IIa, Open Label, Dual Cohort, Triple Center Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for MAGE-A3/A6/B18 or NYESO-1/LAGE in Patients With Recurrent or Treatment Refractory Ovarian Cancer

Inclusion Criteria:

- Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or
fallopian tube carcinoma with refractory or platinum resistant disease and/or have
received ≥ 2 lines of chemotherapy.

- Measurable disease as defined by RECIST Criteria (V1.1)

- HLA-A201 and tumor express NY-ESO-1 and/or LAGE or HLA-A101 then the tumor must
express MAGE-A3 and/or MAGE-A6 and/or MAGE-B18.

- Last chemotherapy, radiotherapy or immunotherapy, or prior investigational agents was
longer than 4 weeks prior to study entry.

- Normal organ and bone marrow function (ANC ≥ 1,500/mcL; Platelets ≥ 100,000/mcL;
Creatinine ≤ 2.0 mg/dL; AST/ALT ≤ 2.5 x ULN; Total Bilirubin WNL; Leucocytes ≥
3,000/mcL)

- Life expectancy of greater than 4 months; ECOG PS of 0 or 1

Exclusion Criteria:

- Pregnant

- Active brain metastases

- Active HIV, Hepatitis B, Hepatitis C infection

- Received an experimental vaccine within 6 months

- Received any previous gene therapy using an integrating vector

- Allergy to Cyclophosphamide, Mesna

- Prior malignancy within the past 3 years (except non-melanoma skin cancer)

- Active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia

- Chronic use of the following within 30 days prior to study entry: corticosteroids,
hydroxyurea or immunomodulating agents (interleukin-2, interferon-alpha, interferon
gamma, granulocyte colony stimulating factors (inhaled steroids OK)